Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04438005 | A Study of ICP-022 in Patients With R/R DLBCL | PHASE2 | COMPLETED | 3 | — | — | May 7, 2020 | Dec 13, 2021 | May 13, 2024 | 7 | China |
The efficacy measured by overall response rate (ORR) according to the 2014 International Working Group NHL
| Arm | Type | Description |
|---|---|---|
| ICP-022 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ICP-022 | DRUG | ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. |
Key Inclusion criteria： 1. Men and women between 18 and 75 years old, 2. Histologically confirmed diffuse large B-cell lymphoma（DLBCL）with MyD88 L265P and CD79B positive, at least one measurable tumor of greater than 1.5 centimeter in long axis by contrast-enhanced CT/MRI, 3. ECOG performance statu...